SCHEMBL6504277

SCHEMBL6504277

COc1ccc(-c2cc3ccccc3[nH]2)cc1NC(=O)N(S)c1cccc(CC(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.46
PPARG P37231 1/20 0.41
SMO Q99835 2/20 0.40
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
CASP3 P42574 1/20 0.38
RAB9A P51151 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
FABP4 P15090 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
NPY5R Q15761 1/20 0.36
VCP P55072 1/20 0.36
GAA P10253 1/20 0.36
ACLY P53396 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6505458 0.91 ALOX15 (0.47) ALOX15PPARGSMOKDM4ENPC1
SCHEMBL6494688 0.83 ALOX15 (0.47) ALOX15PPARGSMOKDM4ENPC1
SCHEMBL6496749 0.82 ALOX15 (0.48) ALOX15SMOKDM4ENPC1MAPT
SCHEMBL6504271 0.81 SMO (0.55) ALOX15PPARGSMOMAPTFABP4
SCHEMBL6501949 0.79 CA12 (0.52) ALOX15SMOKDM4ENPC1MAPT
SCHEMBL6494600 0.79 ALOX15 (0.46) ALOX15SMOKDM4ENPC1MAPT
SCHEMBL6505453 0.77 SMO (0.50) ALOX15PPARGSMOMAPTNR1H4
SCHEMBL6493782 0.76 ACLY (0.38) ALOX15NPC1CASP3RAB9ASENP8
SCHEMBL6503850 0.76 ACLY (0.38) ALOX15NPC1MAPTCASP3RAB9A
SCHEMBL7194220 0.74 ALOX15 (0.36) ALOX15SMOKDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US claimed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP claimed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 ALOX15 1/4885PPARG 1084/4885SMO 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.